Browse the evidence

Women on hormone therapy (HT) had a higher total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months compared to women not on HT.

Practitioners may consider hormone therapy as a factor in weight loss strategies for postmenopausal women.

A greater percentage of women on HT achieved ≥5% and ≥10% total body weight loss at 12 months.

This suggests that hormone therapy may enhance the effectiveness of weight loss treatments.

Tirzepatide significantly decreased food intake and reduced overall appetite scores.

Tirzepatide may help reduce appetite, aiding in weight loss efforts.

The use of GLP-1 receptor agonists (GLP-1RAs) post-bariatric treatment results in a weight reduction of 7.83 kg compared to pre-treatment.

GLP-1RAs can be an effective strategy for weight management in patients after bariatric surgery.

In randomized controlled trials, GLP-1RAs induce a weight reduction of 4.36 kg compared to placebo.

GLP-1RAs can be beneficial for weight loss in a controlled setting post-bariatric surgery.

GLP-1 receptor agonists provide an effective alternative to metabolic surgery and dietary interventions for obesity treatment.

GLP-1 receptor agonists may be recommended as a non-surgical option for managing obesity.

Incretin hormone agonists offer substantial weight reduction and cardiometabolic benefits.

Practitioners can consider incretin hormone agonists as effective options for obesity management.

Weight loss effectively reduces proinflammatory markers and hormones associated with increased risk of endometrioid EC.

Reducing weight can lower the risk factors for endometrial cancer in obese individuals.

Emerging antidiabetic medications show impressive antihyperglycemic effects and remarkable weight loss.

Practitioners should consider these new medications for managing T2D due to their dual benefits.

The dual agonist tirzepatide has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist.

Practitioners may consider tirzepatide as a more effective option for weight loss in obese patients.

GLP-1 receptor agonists produce significant weight loss.

Practitioners can consider GLP-1 receptor agonists as a viable option for weight loss in patients with obesity.

GLP-1 receptor agonists (GLP-1RAs) have proven efficacy in glucoregulation and weight loss.

Practitioners can consider GLP-1RAs as effective treatment options for managing diabetes and obesity.

Tirzepatide facilitated unprecedented weight loss of up to 22.5% in non-diabetic individuals living with obesity.

This indicates that tirzepatide can be a significant option for weight management in obese individuals.

Tirzepatide provides glycemic lowering and weight loss effects.

Tirzepatide may be effective for patients needing to lower blood sugar and lose weight.

GLP-1 receptor agonists decrease weight in people with schizophrenia.

GLP-1 receptor agonists may be considered as a treatment option for weight management in patients with schizophrenia.

Newer antiobesity pharmacotherapies, particularly semaglutide and tirzepatide, have shown greater efficacy for weight reduction compared with older medications.

Newer medications may provide better options for weight management in patients with obesity.

Retatrutide resulted in a percentage change in weight from baseline to 24 weeks ranging from -7.2% to -~18% as the dose increased from 1 mg to 12 mg.

Retatrutide may be an effective treatment option for weight loss in individuals with obesity.

Semaglutide 2.4 mg was associated with significantly greater weight loss compared to placebo in clinical trials lasting 68 weeks.

Semaglutide can be considered an effective pharmacotherapy for weight loss in adults with obesity or overweight.

NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.

NN1706 may be an effective treatment option for weight loss in adults with overweight or obesity.

Effective obesity management is essential to mitigate associated comorbidities and improve quality of life in menopausal women.

Healthcare providers should prioritize obesity management in menopausal women to enhance their health outcomes.

Tailored treatment strategies are necessary to address the unique challenges of obesity management during menopause.

Practitioners should develop individualized obesity management plans for menopausal women.

Tirzepatide resulted in greater hemoglobin A1c reduction from baseline compared to placebo and active comparators, with absolute reductions up to 3.02%.

Tirzepatide may be a more effective option for lowering blood sugar in patients with type 2 diabetes.

Tirzepatide was associated with significant weight loss.

Tirzepatide may aid in weight management for patients with type 2 diabetes.

Tirzepatide shows great efficacy in glycosylated hemoglobin and weight reduction.

Tirzepatide may be effective for improving glycemic control and promoting weight loss in diverse patient groups.